Creation of innovative new drugs through compound-oriented research
First written in FY2016. 2 of 4 entries say "Reframed", first in FY2017. Latest entry: FY2020.
No other company in this theme has enough history to compare yet.
- FY2020RestatedAnnual report
「In drug discovery research, based on the Compound-Oriented drug discovery approach, which focuses on distinctive bioactive lipids and proprietary target molecules to create groundbreaking new drug candidates, we are accumulating disease expertise at the Oncology Research Center, Immunology Research Center, Neurology Research Center and Specialty Research Center established for the respective priority areas. By appropriately identifying medical needs, we are working to create groundbreaking new drugs with a significant medical impact.」
The drug discovery approach based on Compound-Oriented and the accumulation of disease expertise at research centers for each priority area are reaffirmed. - FY2018ReframedAnnual report
「Based on our proprietary Compound-Oriented drug discovery approach, we will concentrate management resources on oncology, immunology and central nervous system diseases as priority research areas, enhance our expertise, and expand research and drug discovery partnerships with external organizations to build a robust pipeline of highly differentiated programs capable of targeting first-in-class drugs.」
The description has expanded from maintaining the Compound-Oriented approach to building a pipeline targeting priority research areas, enhanced expertise, external partnerships and first-in-class drugs. - FY2017ReframedAnnual report
「In the new drug discovery process, we have worked to create original new drugs through a drug discovery approach called “Compound-Oriented,” which accumulates compounds with activity against various targets, such as lipids and enzymes, in libraries and identifies drugs linked to diseases and treatments from those libraries. We have also introduced technologies that enable us to identify compounds associated with diseases and treatments more quickly and accurately, and will continue to advance new drug creation by effectively using our extensive accumulated libraries. Meanwhile, in the strategic areas of cancer treatment and supportive care, we are pursuing the creation of groundbreaking new drugs without being constrained by the Compound-Oriented approach.」
While continuing to use the conventional Compound-Oriented approach and accumulated libraries, the drug discovery policy for the strategic areas of cancer treatment and supportive care has been stated as not being limited to this approach. - FY2016First statedAnnual report
「We have focused on areas such as lipids and enzyme inhibition, accumulated compounds with activity against various targets in libraries, and created original new drugs through a drug discovery approach called “Compound-Oriented,” which identifies drugs linked to diseases and treatments from those libraries.」
This describes the company’s proprietary R&D approach, which starts with compounds and targets rather than diseases.